Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Primary result · Percentage change in UACRResult — go to the resultDifference −52.1 % 95% CI −65.5 to −33.4Authors' conclusion
Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD.
Study context
- Population
- Adults with non-diabetic chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) ≥25 ml min-1 1.73 m-2, urine albumin-to-creatinine ratio (UACR) ≥30 and <3,500 mg g-1) and BMI ≥27 kg m-2; mean age 55.8 years, 39.6% female, median UACR 251 mg g-1, mean eGFR 65.0125 screened
- Participants
- 101 adults
- Comparison
- Semaglutide 2.4 mg per week vs placebo
- Semaglutiden = 51
- Placebon = 50reference
- Primary endpoint
- Percentage change from baseline in UACR
- Follow-up
- Week 24
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
Percentage change in UACR · 24 weeks
Difference
−52.1 %
95% CI −65.5 to −33.4
P < 0.0001
Semaglutidevs Placebo
difference −52.1 % (95% CI −65.5 to −33.4); P < 0.0001
As reported in the abstract
Safety
Events
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Gastrointestinal AEs | 30 | 15 |
Original publication
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. Published 25 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →